Oral fingolimod for relapsing-remitting multiple sclerosis
Doggrell, Sheila Anne (2010) Oral fingolimod for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 11(10), pp. 1777-1781.
Background: Most people with multiple sclerosis have the relapsing-remitting type.
Objective/methods: The objective was to evaluate two clinical trials of fingolimod in relapsing multiple sclerosis.
Results: FREEDOMS (FTY720 Research Evaluation Effects of Daily Oral therapy in Multiple Sclerosis), a Phase III placebo-controlled trial, showed that fingolimod (0.5 or 1.25 mg) reduced the relapse rate and disability in multiple sclerosis, compared to placebo. Fingolimod (0.5 or 1.25 mg) has been compared to interferon β-1a in a Phase III clinical trial (TRANSFORMS; Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis) and shown to be more efficacious than interferon β-1a in reducing relapse rates. However, fingolimod did increase the risk of infections and skin cancers.
Conclusions: Only the lower dose of fingolimod (0.5 mg), which possibly has less toxicity, should be considered for prevention of relapses in relapsing-remitting multiple sclerosis.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.
|Item Type:||Journal Article|
|Keywords:||fingolimod, interferon β-1a, multiple sclerosis|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500) > Clinical Pharmacology and Therapeutics (111502)|
|Divisions:||Past > QUT Faculties & Divisions > Faculty of Science and Technology
Past > Schools > Medical Sciences
|Copyright Owner:||Copyright 2010 Informa Healthcare|
|Deposited On:||03 Nov 2010 04:03|
|Last Modified:||19 Jan 2012 05:32|
Repository Staff Only: item control page